title: Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.
authors.affiliation: Mount Holyoke College, South Hadley, Massachusetts, USA.
authors.forename: Dylan
authors.initials: D
authors.lastname: Shepardson
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA. wrm0@cdc.gov.
authors.forename: William R
authors.initials: WR
authors.lastname: MacKenzie
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000191:economics*; D016527:Drug Costs; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000191:economics*; D055985:Latent Tuberculosis / Q000188:drug therapy* / Q000191:economics*; D012293:Rifampin / Q000031:analogs & derivatives*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin